<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663962</url>
  </required_header>
  <id_info>
    <org_study_id>ANAE-139-08</org_study_id>
    <nct_id>NCT00663962</nct_id>
  </id_info>
  <brief_title>Pregabalin and Post-thoracotomy Pain</brief_title>
  <official_title>A Prospective, Randomized, Double Blinded, Placebo Controlled Pilot Study Assessing the Effect of Perioperative Pregabalin on the Incidence of Chronic Post Thoracotomy Pain Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With Institutional Ethics Board approval and signed informed consent, a pilot investigation
      was conducted in which 15 adult patients scheduled to undergo a thoractomy were randomly
      assigned to receive 1) 150 mg pregabalin 1 hour preoperatively and then 7 days
      postoperatively (BID) or 2) 300 mg pregabalin 1 hour preoperatively and 7 days
      postoperatively (BID) or 3) placebo for same regimen to assess the feasibility, safety and
      compliance of this drug regimen on this patient population. This assessment was necessary in
      order to plan a future fully powered randomized controlled trial looking at the efficacy of
      perioperative pregabalin ifor reducing the incidence/severity of chronic post-thoracotomy
      pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic post thoracotomy pain syndrome (CPTPS) is a significant problem that has important
      effects on patients' daily activities. The severity of postoperative pain and the central
      sensitization associated with it are thought to play a role in the chronification of acute
      pain. Gabapentin has been shown to be effective in reducing acute post-surgical pain and
      treating CPTPS. There is conflicting data regarding its effects on the development of chronic
      post-surgical pain. Although pregabalin is similar to gabapentin there are only a few studies
      examining its use in the modification of post-surgical pain but evidence suggests that it
      might be effective. There are no studies examining the effect of pregabalin on the
      development of chronic post-surgical pain. Our hypothesis is that perioperative use of
      pregabalin will decrease the incidence of CPTPS. Our ultimate goal is to conduct a
      multi-center study assessing the effect of perioperative oral pregabalin on the development
      of CPTPS. Prior to this, we will carry out a prospective, randomized, placebo controlled,
      double-blinded pilot study to assess the feasibility, safety, and compliance associated with
      perioperative use of oral pregabalin in patients undergoing video assisted thoracotomy
      surgery (VATS) or open thoracotomy procedures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome Measure for the Final Study Will be the Incidence of CPTPS at 2 Months.</measure>
    <time_frame>2, 4, and 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Chronic Post-thoracotomy Pain at 2 Months Postoperatively</measure>
    <time_frame>2 months postoperatively</time_frame>
    <description>Incidence of post-thoracotomy pain syndrome (persistent continuous or intermittent chest pain with resting pain score &gt; 4 on a 10 point NRS scale)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Perioperative pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-operatively (n=3) or Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-operatively (n=4).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op. (N=8)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>PHASE 1 (N=3) Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.
PHASE 2 (N=4) Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.</description>
    <arm_group_label>Perioperative pregabalin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op (N=8)</description>
    <arm_group_label>Placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective thoracotomy (ET) or video assisted thoracotomy (VAT);

          -  Understanding and provision of written informed consent;

          -  Age &gt; 18 and &lt; 75;

          -  ASA class I, II or III.

        Exclusion Criteria:

          -  Inability to adhere to study protocol;

          -  Intolerance or known hypersensitivity to any agents to be used in the study;

          -  Contraindication to thoracic epidural placement in open thoracotomy patients;

          -  Inability to respond to the study questionnaire;

          -  Renal insufficiency (serum creatinine &gt; 1.5 x upper limit of normal);

          -  BMI &gt; 40;

          -  Confounding procedural factors which might affect validity of data;

          -  Surgery for tumour extending into the chest wall;

          -  Requirement for second thoracotomy or re-occurrence of disease after surgery;

          -  Potential interaction with study medications and patient's current medications;

          -  Current ETOH or substance abuse;

          -  Pre-existing chronic pain requiring chronic analgesic use;

          -  History of seizure disorder requiring treatment with an anti-convulsant;

          -  Current therapy with thiazolidinedione class oral hypoglycemic agents (e.g. Actos,
             Avandia, or Avandamet);

          -  History of congestive heart failure;

          -  Major psychiatric disorder;

          -  Insufficient safety data in a specific patient population;

          -  Pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge E Zamora, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology Queen's University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <results_first_submitted>January 31, 2013</results_first_submitted>
  <results_first_submitted_qc>January 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 29, 2016</results_first_posted>
  <last_update_submitted>January 29, 2016</last_update_submitted>
  <last_update_submitted_qc>January 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. Jorge Zamora</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Thoracotomy</keyword>
  <keyword>Post-surgical</keyword>
  <keyword>Pregabalin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>REB approval from our institution was received to enroll 15 patients, who had given written informed consent, into this pilot study. All elective ASA I – III patients aged 18 – 75 scheduled for open thoracotomy or video assisted thoracotomy (VAT) were screened for inclusion in this study.</recruitment_details>
      <pre_assignment_details>Thirty-nine patients were screened between April 23 and November 27, 2008. Fifteen patients were eligible for inclusion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pregabalin</title>
          <description>PHASE 1 (N=3) Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.
PHASE 2 (N=4) Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op. (N=8)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6">1 patient excluded for somnolence and unblinded--in 300mg group</participants>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>somnolence</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Of the 7 participants randomized to the pregabalin group, 3 receieved 150mg of pregabalin while 4 recieved 300mg pregabalin.</population>
      <group_list>
        <group group_id="B1">
          <title>Pregabalin</title>
          <description>PHASE 1 (N=3) Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.
PHASE 2 (N=4) Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op. (N=8)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.6" spread="17.6"/>
                    <measurement group_id="B2" value="55.0" spread="18.6"/>
                    <measurement group_id="B3" value="57.6" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome Measure for the Final Study Will be the Incidence of CPTPS at 2 Months.</title>
        <time_frame>2, 4, and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Chronic Post-thoracotomy Pain at 2 Months Postoperatively</title>
        <description>Incidence of post-thoracotomy pain syndrome (persistent continuous or intermittent chest pain with resting pain score &gt; 4 on a 10 point NRS scale)</description>
        <time_frame>2 months postoperatively</time_frame>
        <population>pilot study--convenience</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin 150mg (N=3) administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.
or Pregabalin 300mg (N=4)administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op. (N=8)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Chronic Post-thoracotomy Pain at 2 Months Postoperatively</title>
          <description>Incidence of post-thoracotomy pain syndrome (persistent continuous or intermittent chest pain with resting pain score &gt; 4 on a 10 point NRS scale)</description>
          <population>pilot study--convenience</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pregabalin</title>
          <description>Pregabalin 150mg (N=3) administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.
or Pregabalin 300mg (N=4)administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op. (N=8)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>somnolence</sub_title>
                <description>sleepiness with 300 mg pregabalin</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pregabalin and Post-thoracotomy pain</name_or_title>
      <organization>Queen's University</organization>
      <phone>(613) 548-7827</phone>
      <email>zamoraj@kgh.kari.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

